Viemed Healthcare, Inc. (VMD) is a Healthcare stock trading at $9.09 (as of 2026-08-25), with a market capitalization of $348.48M and a trailing P/E of 30.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment (DME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company also leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), percussion vests, oxygen concentrator units, and other small respiratory equipment; and sells and rents DME and patient medical services. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management related solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
Viemed rents and sells respiratory equipment (ventilators, PAP machines, pulse oximeters) to U.S. patients with breathing conditions, billing Medicare and commercial insurers. Revenue is recurring, driven by growing patient panels across sleep therapy and ventilator rentals rather than one-time sales.
Profit comes from the recurring resupply and rental cycle, not the initial equipment sale: once a patient is on a PAP machine or ventilator, they generate steady monthly revenue for years.
Business quality (Mixed): Mixed. Gross margin of 58% is healthy for DME, but the gap down to a 6% operating margin signals a heavy cost base (logistics, billing, SG&A) that limits earnings leverage as the company scales.
Valuation: At 30× earnings, VMD trades 19% above the Healthcare Services average (25×).
| Price | $9.09 |
| Market Cap | $348.48M |
| P/E Ratio | 30.1 |
| EV / EBITDA | 9.9 |
| Price / Book | 2.39 |
| Price / Sales | 1.16 |
| FCF Yield | 3.9% |
| DCF Value (model) | $7.07 |
| DCF Upside vs Price | -22.2% |
| Revenue (TTM) | $270.28M |
| Net Margin | 5.5% |
| Revenue Growth (YoY) | 20.5% |
| EPS Growth (YoY) | 31.0% |
| FCF Growth (YoY) | 805.2% |
| Altman Z-Score | 6.29 (safe) |
| Piotroski F-Score | 6/9 (moderate) |
| Stock P/E | 30.1 |
| Sector P/E (Healthcare) | 21.9 |
| Industry P/E (Healthcare Services) | 25.4 |
| vs Sector | 37.3% |
| vs Industry | 18.5% |
| Top Institutional Holder | BlackRock, Inc. ($42.57M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Healthcare Services |
| CEO | Casey Hoyt |
| Employees | 1,222 |
| Country | US |
| IPO Date | 2019-08-09 |
Data as of 2026-08-25.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.